Combined molecular and functional brain imaging (PET/MR) to predict treatment response to neuropharmacological treatment

Phase 1

• Conditions: Major depressive disorder; Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]

• Registration Number: EUCTR2014-001550-42-AT
• Lead Sponsor: Medizinische Universität Wien

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05-07
• Last Update Posted: 8 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 195

Inclusion Criteria

General health based on medical history, physical examination and structured clinical interview for DSM-IV (SCID)
Age 18 to 55 years
HAM-D >17 (MDD patients)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 195
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Any medical, psychiatric or neurological illness (other than MDD)
Psychopharmacological treatment within 3 months prior to inclusion (excepting occasional intake of antihistamines and benzodiazepines, given a wash-out of at least one day prior to PET/MR measurements)
Current or former substance abuse (excepting nicotine)
Pregnancy
Any implant or stainless steel graft or any other contraindications for MRI
Participation in studies involving radiation exposure in the past 10 years.
Body mass index <17 or >30

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified